Literature DB >> 10953127

Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

B Schurch1, M Stöhrer, G Kramer, D M Schmid, G Gaul, D Hauri.   

Abstract

PURPOSE: We evaluated the efficacy of botulinum-A toxin injections into the detrusor muscle in patients with spinal cord injury, detrusor hyperreflexia and urge incontinence resistant to anticholinergic drugs. The purpose of treatment was to suppress incontinence episodes and increase functional bladder capacity.
MATERIALS AND METHODS: Included in our prospective nonrandomized study done at 2 clinics were 31 patients with traumatic spinal cord injury who emptied the bladder by intermittent self-catheterization. These patients had severe detrusor hyperreflexia and incontinence despite a high dose of anticholinergic medication. Pretreatment evaluation included a clinical examination and complete urodynamic investigation. Under cystoscopic control a total of 200 to 300 units of botulinum-A toxin were injected into the detrusor muscle at 20 to 30 sites (10 units per ml. per site), sparing the trigone. Clinical and urodynamic followup was planned for 6, 16 and 36 weeks after treatment. Patients were asked to decrease their intake of anticholinergic drugs during week 1 after treatment.
RESULTS: Of the 21 patients 19 underwent a complete examination 6 weeks after the botulinum-A toxin injections, and 11 at 16 and 36 weeks. At the 6-week followup complete continence was restored in 17 of 19 cases in which anticholinergic medication was markedly decreased or withdrawn. Less satisfactory results in 2 cases were associated with an insufficient dose of 200 units botulinum-A toxin. After the injections overall mean reflex volume and mean maximum cystometric bladder capacity plus or minus standard deviation significantly increased from 215.8 +/- 90.4 ml. to 415.7 +/- 211.1 (p <0.016) and 296.3 +/- 145.2 to 480.5 +/- 134.1 (p <0.016), respectively. There was also a significant decrease after treatment in mean maximum detrusor voiding pressure from 65.6 +/- 29.2 cm. water to 35 +/- 32. 1 (p <0.016). Mean post-void residual urine volume catheterized at the end of the urodynamic examination increased significantly from a mean of 261.8 +/- 241.3 ml. to 490.5 +/- 204.8 (p <0.016). Moreover, autonomic dysreflexia associated with bladder emptying that manifested as a hypertensive crisis during voiding disappeared after treatment in the 3 patients with tetraplegia. Satisfaction was high in all successfully treated patients and no side effects were observed. Ongoing improvement in urodynamic parameters and incontinence was already present in all patients reevaluated at 16 and 36 weeks.
CONCLUSIONS: Botulinum-A toxin injections into the detrusor seem to be a safe and valuable therapeutic option in spinal cord injured patients with incontinence resistant to anticholinergic medication who perform clean intermittent self-catheterization. Successfully treated patients become continent again and may withdraw from or markedly decrease anticholinergic drug intake. A dose of 300 units botulinum-A toxin seems to be needed to counteract an overactive detrusor. The duration of bladder paresis induced by the toxin is at least 9 months, when repeat injections are required.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953127     DOI: 10.1097/00005392-200009010-00018

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  169 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 2.  Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Authors:  Jürg Kesselring
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults.

Authors:  Douglas G Tincello
Journal:  World J Urol       Date:  2011-10-15       Impact factor: 4.226

4.  Botulinum toxin and urinary bladder disorders in women: new insight into an old problem.

Authors:  Ervin Kocjancic; Diaa E E Rizk
Journal:  Int Urogynecol J       Date:  2010-04-01       Impact factor: 2.894

Review 5.  [Intravesical treatment of overactive bladder syndrome].

Authors:  A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

6.  Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela Paraiso; Shawn A Menefee; Joseph Schaffer; John Wei; Toby Chai; Nancy Janz; Cathie Spino; Susan Meikle
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

Review 7.  Botox in urology.

Authors:  Ali Thwaini; Iqbal Shergill; Suresh Radhakrishnan; Frank Chinegwundoh; Hadeel Thwaini
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-11-19

8.  Botulinum toxin in neurogenic detrusor overactivity.

Authors:  Carlos Arturo Levi D'Ancona; Rúiter Silva Ferreira; Mauricio Carneiro Rassi
Journal:  Int Neurourol J       Date:  2012-09-30       Impact factor: 2.835

Review 9.  Botulinum toxin in paediatric urology: a systematic literature review.

Authors:  Ranan DasGupta; Feilim Liam Murphy
Journal:  Pediatr Surg Int       Date:  2008-10-25       Impact factor: 1.827

Review 10.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.